Compare Ascendis Pharma A/S (ASND) vs Emerson Electric Co. (EMR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Emerson Electric Co. — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Emerson Electric Co. trades at $137.64 (market cap $77.79B). The key difference: Emerson Electric Co. is far larger — about 4.4× Ascendis Pharma A/S's market cap, and Emerson Electric Co. pays a 1.6% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | EMR | |
|---|---|---|
Market Cap | $17.74B | $77.79B |
Sector | Health | Industrials |
52-Week High | $277.18 | $161.69 |
52-Week Low | $163.32 | $123.30 |
Enterprise Value | $18.11B | $90.05B |
Dividend Yield | — | 1.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Emerson Electric (EMR) trades at $138.88, up 0.78% today, with a bearish technical signal from moving averages. The stock shows stable revenue growth, with 2025 revenue of $18.02B and net income of $2.29B, supported by a strong gross profit margin of 52.67%. Recent news highlights investor attention and collaboration with Aramco on corrosion R&D, while the Intelligent Devices segment gains momentum.
EMR presents a mixed outlook: analyst consensus is bullish with a $157.60 price target, but technical indicators suggest near-term pressure. Key risks include volatile cash flows and competitive pressures in manufacturing electronics. The stock's valuation at a P/E of 32.15 may limit upside unless earnings accelerate.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Emerson Electric Co.
Emerson Electric is a multi-industrial conglomerate that operates under two business platforms: automation solutions and commercial and residential solutions. The latter is further subdivided into two operating segments: climate technologies, which sells HVAC and refrigeration products and services as well as tools and home products, which sells tools and compressors, among other products and services. Commercial and residential solutions boasts several household brands, including Copeland and RIDGID. Automation solutions is most known for its process manufacturing solutions, which consists of measurement instrumentation, as well as valves and actuators, among other products and services. Roughly half of the firm's geographic sales take place in the United States.
Read more on EMR →
